Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab
Research questions benematch of latest Alzheimer’s drug (UGA Immediately): Final summer, the U.S. Meals and Drug Administration fully permitted the primary ...